<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201214049718N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-25</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of melatonin on sleep quality, mental health and performance in patients with drug abuse in methadone-treated patients</public_title>
      <acronym></acronym>
      <scientific_title>The effect of melatonin on sleep quality, mental health and performance in patients with drug abuse in methadone-treated patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>105</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53047</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: The randomization process is a simple randomization method using Random allocation software . We list the people who have the inclusion criteria and consent to participate in the study according to the three digits to the right of the national code from 1 to 105 and then using Random allocation software is divided into three groups a: Melatonin, group b: Zolpidem, group c: control. In front of each number, the assigned group is created, Blinding description: Responsible for collecting questionnaire information and analyzing statistics will be unaware of the placement of people in groups. Coding of people is done based on the first name and surname and father's name and the last three digits of the national code. Does not know about the assignment of individuals in groups, will give the questionnaires to the participants before and one month after the start of the study and enters the data into SPSS and this data will be analyzed by the analyzer if it is not in the coding process.</study_design>
      <phase>3</phase>
      <hc_freetext>Patients with drug abuse, people treated with methadone.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: In this group, patients will use three 3 mg melatonin tablets made by Razak company half an hour before bedtime for 4 weeks. In addition to melatonin, these patients receive methadone syrup made by Darou Pakhsh Company in the morning and evening (4 hours before bedtime) according to the required dose for 4 weeks. Intervention 2: intervention group 2: In this group, patients will take a 10 mg zolpidem tablet made by Sobhan Company for 4 weeks before bedtime. In addition to zolpidem, these patients receive methadone syrup made by Darou Pakhsh Company in the morning and evening (4 hours before bedtime) according to the required dose for 4 weeks. Intervention 3: Control group: In this group, patients will take a capsule filled with starch as placebo for 4 weeks at night before bedtime. In addition to placebo, these patients will receive methadone syrup made by Darou Pakhsh Company in the morning and evening (4 hours before bedtime) according to the required dose for 4 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Total potential data is shareable after unre identifying people

When:
Starting access period 6 months after printing results

To whom:
It will be available for researchers working in academic and scientific institutions, as well as those working in the industry

Conditions:
Use in other articles

Where to obtain:
zahraamini63@gmail.com

How to obtain:
After reading the e-mail and preparing the request answer, the answer will be given as soon as possible

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Amini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Preventive &amp; Community Medicine Community Medicin Department Isfahan University of Medical Sciences</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3274 7970</telephone>
        <email>zahraamini63@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Amini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Preventive &amp; Community Medicin Community Medicine Department Isfahan University of Medical Sciences</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3274 7970</telephone>
        <email>zahraamini63@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness to participate in research
Over 18 years of age
Having writing literacy 
Substance abuse confirmed by positive urine tests
PSQI score above 5
No neurological, neuro-psychotic or autoimmune disease, cancer, lung disease, class 4 heart failure or unstable angina
No taking benzodiazepines, anticonvulsants, aspirin, beta-blockers, calcium channel blockers, NSAIDs, dexamethasone, lithium, melatonin, and antidepressants such as serotonin reuptake inhibitors.
Not working in night shift 
Taking  methadone for at least 3 months</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>If there is a crisis or un foreseeable disaster during the research.
Changes in treatment protocol for any reason before the intervention
Sever allergic reaction to melatonin and zolpidem
Pregnancy or Lactation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z71.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Drug abuse counseling and surveillance</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: In this group, patients will use three 3 mg melatonin tablets made by Razak company half an hour before bedtime for 4 weeks. In addition to melatonin, these patients receive methadone syrup made by Darou Pakhsh Company in the morning and evening (4 hours before bedtime) according to the required dose for 4 weeks.</i_keyword>
      <i_keyword>intervention group 2: In this group, patients will take a 10 mg zolpidem tablet made by Sobhan Company for 4 weeks before bedtime. In addition to zolpidem, these patients receive methadone syrup made by Darou Pakhsh Company in the morning and evening (4 hours before bedtime) according to the required dose for 4 weeks.</i_keyword>
      <i_keyword>Control group: In this group, patients will take a capsule filled with starch as placebo for 4 weeks at night before bedtime. In addition to placebo, these patients will receive methadone syrup made by Darou Pakhsh Company in the morning and evening (4 hours before bedtime) according to the required dose for 4 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sleep Quality Score in Petzburg Sleep Quality Questionnaire. Timepoint: Before and 4 weeks after intervention. Method of measurement: Petzburg Sleep Quality Questionnaire.</prim_outcome>
      <prim_outcome>Mental health score in Depression, Anxiety, Stress Scale-21. Timepoint: Before and 4 weeks after intervention. Method of measurement: Depression, Anxiety, Stress Scale-21.</prim_outcome>
      <prim_outcome>Sexual function score in Internation Index of Erectile Function Questionnaire. Timepoint: Before and 4 weeks after intervention. Method of measurement: Internation Index of Erectile Function Questionnaire.</prim_outcome>
      <prim_outcome>General health score in General Health Questionnaire-28. Timepoint: Measurement of general health score before the intervention and 4 weeks after the taking of melatonin or zolpidem or placebo. Method of measurement: General Health Questionnaire-28.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-12-12</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Building 56, No. 6, Khaju St Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
